General American Investors’s Aratana Therapeutics, Inc. PETX Stock Holding History

General American Investors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,415,824	Closed	-$7.31M	–	72
2019 Q2	$7.31M	Sell	1,415,824 -1,102	-0.1%	-$4.95K	0.69%	48
2019 Q1	$5.1M	Sell	1,416,926 -182,439	-11%	-$791K	0.51%	54
2018 Q4	$9.8M	Sell	1,599,365 -274,999	-15%	-$1.68M	1.03%	42
2018 Q3	$10.9M	Buy	1,874,364 +256,441	+16%	+$1.28M	0.94%	48
2018 Q2	$6.88M	Hold	1,617,923	–	–	0.63%	53
2018 Q1	$7.13M	Buy	1,617,923 +500,000	+45%	+$2.23M	0.68%	49
2017 Q4	$5.88M	Buy	1,117,923 +250,323	+29%	+$1.53M	0.57%	50
2017 Q3	$5.32M	Buy	867,600 +248,940	+40%	+$1.58M	0.5%	53
2017 Q2	$4.47M	Buy	618,660 +94,201	+18%	+$579K	0.45%	51
2017 Q1	$2.78M	Buy	524,459 +38,991	+8%	+$263K	0.27%	54
2016 Q4	$3.49M	Buy	485,468 +73,367	+18%	+$593K	0.35%	55
2016 Q3	$3.86M	Hold	412,101	–	–	0.39%	54
2016 Q2	$2.6M	Buy	+412,101	New	+$2.65M	0.27%	52

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

General American Investors's PETX Position: Q3 2019 in Review

General American Investors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 1,415,824 shares — an estimated $7.31M sold.

General American Investors first reported a position in PETX in Q2 2016 and held it in 13 quarters. The position peaked at $10.9M in Q3 2018. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

General American Investors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
General American Investors sold 1,415,824 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $7.31M.
General American Investors first reported a position in Aratana Therapeutics, Inc. in Q2 2016 and held it in 13 quarters.
General American Investors's Aratana Therapeutics, Inc. position peaked at $10.9M in Q3 2018.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on General American Investors's 13F filing for Q3 2019, filed 25 Oct 2019.